1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Biotechnology
China NT Pharma Group Co., Ltd.

China NT Pharma Group Co., Ltd.

HHKEX:1011
0.29
HKD
-0.03
(-9.52%)
552.88MMarket Cap
China NT Pharma Group Co., Ltd.
HKEX:1011
(Hong Kong Exchange)

Recent

price

0.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
32.88
27.55
6.83
6.97
7.99
5.98
2.32
3.92
3.65
0.87
1.18
1.2
- -
0.04
0.14
0.04
- -
Revenue per Share
1.58
2.34
-10.25
-6.22
0.02
0.62
0.75
1.07
-6.12
-3.33
-1.9
-0.79
-0.35
-0.73
-0.2
-0.04
- -
Basic EPS, GAAP
-5.37
-2.92
-0.47
-0.52
-0.42
-0.98
-4.54
-1.29
-2.33
-0.22
0.01
-0.72
0.17
0.19
-0.04
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.09
0.22
0.36
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.5
18.86
8.18
1.93
1.97
5.71
6.59
7
3.05
0.55
0.09
-1.11
-1.27
-1.29
-1.51
-0.41
-0.41
Book Value per Share
4.15
18.39
7.97
1.52
1.61
4.86
-0.83
-1.36
-4.97
-5.57
-0.77
-1.95
-2.1
-1.29
-1.51
-0.41
-0.41
Tangible Book Value per Share
81
100
108
108
108
142
155
154
157
176
189
189
190
198
264
617
616
Basic Weighted Avg Shares
2,668
2,758
739
754
865
848
360
605
572
153
222
227
- -
7
38
24
- -
Sales/Revenue/Turnover
9.58
12.18
-58.88
-26.21
6.57
18.65
16.24
42.16
10.59
-35.16
-37.4
-43.47
- -
-763.07
-51.43
-51.18
- -
Operating Margin (%)
17
24
28
27
23
16
23
34
36
31
24
42
21
6
1
1
- -
Depreciation Expense
129
234
-1,109
-673
2
88
116
165
-958
-588
-358
-150
-66
-144
-53
-26
- -
Net Income, GAAP
38.42
23.77
- -
- -
87.96
12.92
30.51
7.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.82
8.5
-150.08
-89.3
0.24
10.34
32.31
27.31
-167.56
-382.87
-161.28
-65.96
- -
-1,949.36
-140.56
-107.79
- -
Profit Margin (%)
217
1,736
508
145
-82
337
-383
-118
-751
-1,316
-579
-628
-1,096
-653
-709
-606
-606
Working Capital
- -
- -
20
310
120
- -
- -
- -
4
68
52
214
- -
4
8
- -
- -
LT Debt
502
2,055
885
209
213
903
1,039
1,429
492
102
22
-211
-242
-340
-399
-274
-274
Total Equity
- -
13.68
- -
- -
4.31
27.68
4.71
17.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
13.89
- -
- -
1.34
10.86
8.78
10.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
18.55
-75.85
-123.14
0.99
15.9
12.12
15.6
-121.23
-197.66
-588.46
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
368
316
317
LT Borrowings
8
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
264
674
674
Market Capitalization
67
258
497

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
16
28
15
Cash, Cash Equivalents & STI
10
5
7
Accounts Receivable, Net
- -
23
2
Inventories
- -
- -
- -
Total Current Liabilities
725
621
621
Payables & Accruals
- -
- -
- -
ST Debt
368
316
317
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-117.2%
-200.34%
-31.39%
Free Cash Flow
-591.01%
-1,226.26%
-39.98%
Net Income, GAAP
-79.44%
-22.31%
-51.19%
Sales/Revenue/Turnover
- -
- -
-36.36%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
7
2024
- -
- -
38
2025
- -
- -
24

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.73
2024
- -
- -
-0.2
2025
- -
- -
-0.04

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
China NT Pharma Group Company Limited (1011.HK), an investment holding company founded in 1995 and headquartered in Central, Hong Kong, engages in the research, development, manufacturing, sales, and distribution of pharmaceutical products primarily in the People's Republic of China. The company manufactures, sells, and trades prescription medicines targeting tumor and blood system diseases, digestive system diseases, central nervous system diseases, respiratory system diseases, and other therapeutic areas; produces and markets NT branded products and generic drugs; and offers marketing, promotion, logistics, and consulting services to pharmaceutical suppliers. It operates through digital services and sales agency segments, acting as an agent for medical and health-related products, with subsidiaries and operations spanning Shanghai, Beijing, Guangzhou, Suzhou, Taizhou, Hainan, and other locations across China, supported by three pharmaceutical factories for contract manufacturing and branded production. Historically a leading provider of vaccine supply chain, promotion, and sales services—once the largest comprehensive vaccine distributor in China covering over 79% of disease control centers—the company has shifted focus to digital healthcare, bone health platforms under the "福艾蒙" brand integrating drugs, devices, rehabilitation, and digital medical services, and orthopedic markets with AI-powered bone density analysis systems and orthopedic drugs. Recent developments include the 2020 establishment of Beijing Kangchen Biotechnology Co., Ltd., a joint venture with Kangchen Pharmaceutical invested at RMB 900 million, focusing on the "密盖息" brand for bone health services with OEM factories in Germany and France, over 150 employees, and annual sales exceeding RMB 300 million; acquisition of commercial rights to global top-10 new drug olitumomab (奥替单抗) in Greater China plus Southeast Asia, advancing to U.S. Phase II trials; and clarification of financial figures in a major acquisition announced in 2025, alongside a strategic pivot to digital services businesses. The group maintains partnerships with multinational firms such as GlaxoSmithKline, Pfizer, Sanofi-Pasteur, and Novartis, serving nationwide medical networks, grassroots institutions, and international markets through its integrated supply chain capabilities.